Fig. 1 · Structure
Documents & Downloads
Datopotamab deruxtecan
TROP2 ADC
Datopotamab deruxtecan is a TROP2-targeted antibody-drug conjugate (ADC) designed for potent antitumor activity. This compound effectively delivers cytotoxic agents to TROP2-expressing cells, making it valuable in cancer research and therapeutic development. Its mechanism of action supports investigations into targeted therapies for tumors that overexpress the TROP2 antigen.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 2238831-60-0 |
| Applications | TROP2 ADC |
| Molecular Weight | 149000 (average) |
| Synonyms | DS-1062; Dato-DXd |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.